A subsidiary of French nanotechnology expert Nanobiotix (Euronext: NANO), Curadigm, has been selected for the Sanofi (Euronext: SAN) iTech awards program, as a “highly promising option” to improve gene therapies.
Curadigm is an early-stage nanotechnology company aiming to increase drug bioavailability while decreasing unintended off-target effects, specifically liver toxicity.
The firm’s Nanoprimer platform - invented at Nanobiotix and licensed to Curadigm for development and commercialization - can be used with most intravenous therapeutics across multiple drug classes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze